Innocrin Pharmaceuticals is developing small-molecule CYP17 lyase-selective inhibitors to treat...
$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain...
GlobalData’s Healthcare Industry Analyst says the rise in biotech peer group total revenue over...
Cuts to global health research budgets and people’s wariness of vaccines could hamper efforts to improve health around the world.
Shares of Arena Pharmaceuticals rose Tuesday after the drug developer said it received an additional patent for its weight loss drug Belviq.
Arvinas announced a strategic collaboration with Merck with the goal of creating novel therapeutics based on protein degradation.
The cash payment under the Nektar-AstraZeneca agreement was triggered by the first commercial sale of MOVANTIK (naloxegol) in the U.S.
An Irish healthcare company has launched a crowdfunding campaign on Indiegogo to raise funds to research and develop affordable medical cannabis.
Cellceutix Corporation, a clinical stage biopharmaceutical company, has signed a $30 million stock purchase agreement with Aspire Capital Fund, LLC.
The U.S. treatment market for Rheumatoid Arthritis (RA) is set to increase in value from $6.4 billion in 2013 to $9.3 billion by 2020.
Analyst Rob Goldman says mid-stage biotech companies are being built for potential sale, in an environment of increasing mergers and acquisitions.
What does it cost to miss a deadline? For the company that makes the prescription painkiller Oxycontin, the answer could be more than $1 billion.
Dow Chemical is breaking off a significant portion of its chlorine operations in a deal valued at $5 billion.
A new report expects the market value for sepsis treatments to increase more than thirteen-fold between 2016 and 2021 following the launch of a new sepsis-specific drug.
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for the expansion of its fill/finish facility in Hillsboro, Oregon.
Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.
The Supreme Court is taking up a challenge by industry groups and Republican-led states that want to roll back Obama administration environmental rules aimed at reducing power plant emissions of mercury and other hazardous air pollutants that contribute to respiratory illnesses, birth defects and developmental problems in children.
Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.
House Republicans quietly deepened recommended budget savings from the government's chief health care program for the poor by about $140 billion in recent weeks to offset part of the cost of higher payments to doctors who treat Medicare patients, according to officials familiar with the tradeoff.
BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
The World Health Organization denied that politics swayed the decision to declare an international emergency over the spread of the Ebola virus last year, despite evidence senior staffers repeatedly discussed the diplomatic and economic fallout of such a move.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
A recent report found the pharmaceutical industry increased its contribution to the global economy between 2006 and 2012.
Over nearly two decades, inventions and products licensed by academic institutions contributed more than $1 trillion to the U.S. economy, according to a recent report from the Biotechnology Industry Organization.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. The transaction is expected to close on 31 March 2015.
- Page 1